194 related articles for article (PubMed ID: 24293258)
1. Chronic myeloid leukemia patient with co-occurrence of BCR-ABL junction and JAK2 V617F mutation.
Xu W; Chen B; Tong X
Int J Hematol; 2014 Jan; 99(1):87-90. PubMed ID: 24293258
[TBL] [Abstract][Full Text] [Related]
2. Clinical and laboratory relevance of JAK2 V617F and BCR-ABL co-existence in Philadelphia positive CML patients.
Ahmad N; Qayum S; Jameel A; Ali A; Siraj S; Ali J; Yousafzai YM
Pak J Pharm Sci; 2021 Nov; 34(6(Supplementary)):2289-2295. PubMed ID: 35039265
[TBL] [Abstract][Full Text] [Related]
3. A case of double positive myeloproliferative neoplasm: A diagnostic and therapeutic challenge.
Shaikh AB; Aribandi A; Gupta A; Subramanian SK; Goyal M
Indian J Pathol Microbiol; 2021; 64(4):820-823. PubMed ID: 34673614
[TBL] [Abstract][Full Text] [Related]
4. A man with concomitant polycythaemia vera and chronic myeloid leukemia: the dynamics of the two disorders.
Bee PC; Gan GG; Nadarajan VS; Latiff NA; Menaka N
Int J Hematol; 2010 Jan; 91(1):136-9. PubMed ID: 20047097
[TBL] [Abstract][Full Text] [Related]
5. A 68-Year-Old Man with a Cytogenetic Diagnosis of Chronic Myeloid Leukemia and Bone Marrow Findings of Philadelphia Chromosome Translocation Between the Long Arm of Chromosomes 9 and 22, Leading to the BCR-ABL1 Fusion Gene and V617F Mutation in the JAK2 Gene.
Warsi A; Alamoudi S; Alsuraihi AK; Althobaiti M; Daghistani M; Samarin K; Alahmadi MO; Abuyabis RG; Bogari RA; Filimban SA
Am J Case Rep; 2023 Mar; 24():e938488. PubMed ID: 36864712
[TBL] [Abstract][Full Text] [Related]
6. Feasibility of Qualitative Testing of BCR-ABL and JAK2 V617F in Suspected Myeloproliperative Neoplasm (MPN) Using RT-PCR Reversed Dot Blot Hybridization (RT-PCR RDB).
Masykura N; Habibah U; Selasih SF; Gani S; Irawan C; Somoastro S; Handoyo Utomo AR
Clin Lymphoma Myeloma Leuk; 2019 Apr; 19(4):220-227. PubMed ID: 30772299
[TBL] [Abstract][Full Text] [Related]
7. The concomitant occurrence of JAK2V617F mutation and BCR/ABL transcript with phenotypic expression - an overlapping myeloproliferative disorder or two distinct diseases? - case report.
Ursuleac I; Colita A; Adam T; Jardan C; Ilea A; Coriu D
J Med Life; 2013 Mar; 6(1):34-7. PubMed ID: 23599815
[TBL] [Abstract][Full Text] [Related]
8. [Analysis of Clinical Characteristics of JAK2 V617F and BCR-ABL Double-Mutant Myeloproliferative Neoplasms].
Yan J; Ding YW; Wang PY; Wu YP; Zhang HC; Liu LH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Oct; 29(5):1540-1547. PubMed ID: 34627437
[TBL] [Abstract][Full Text] [Related]
9. Thrombocytosis and STAT5 activation in chronic myelogenous leukaemia are not associated with JAK2 V617F or calreticulin mutations.
Turakhia SK; Murugesan G; Cotta CV; Theil KS
J Clin Pathol; 2016 Aug; 69(8):713-9. PubMed ID: 26754830
[TBL] [Abstract][Full Text] [Related]
10. Co-existence of
Frikha R; Turki F; Kassar O; Elloumi M; Kamoun H
J Oncol Pharm Pract; 2021 Oct; 27(7):1784-1789. PubMed ID: 33567976
[TBL] [Abstract][Full Text] [Related]
11. Unique Case of Myeloproliferative Neoplasm with Two Rare Clonal Abnormalities: Rare JAK2 Exon 12 Mutation and Rare e14a3 (b3a3) BCR/ABL Fusion Transcript.
Swaminathan M; Patel KP; Huynh-Lu J; Tang G; Zuo Z; Miranda R; Verstovsek S
Acta Haematol; 2019; 141(1):23-27. PubMed ID: 30463063
[TBL] [Abstract][Full Text] [Related]
12. Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group.
Soderquist CR; Ewalt MD; Czuchlewski DR; Geyer JT; Rogers HJ; Hsi ED; Wang SA; Bueso-Ramos CE; Orazi A; Arber DA; Hexner EO; Babushok DV; Bagg A
Mod Pathol; 2018 May; 31(5):690-704. PubMed ID: 29327708
[TBL] [Abstract][Full Text] [Related]
13. Expansion of a BCR-ABL clone in a JAK2 V617F myeloproliferative neoplasm treated by ruxolitinib.
Luque Paz D; Ianotto JC; Chauveau A; Guibourg B; Lecucq L; Lippert E; Ugo V
Ann Hematol; 2016 Jan; 95(2):349-50. PubMed ID: 26459144
[No Abstract] [Full Text] [Related]
14.
Tarantini F; Cumbo C; Zagaria A; Parciante E; Anelli L; Coccaro N; Tota G; Minervini CF; Redavid I; Rossi AR; Conserva MR; Specchia G; Musto P; Albano F
Hematology; 2022 Dec; 27(1):842-846. PubMed ID: 35938951
[TBL] [Abstract][Full Text] [Related]
15. Rare Case of Accelerated-Phase Chronic Myeloid Leukemia Diagnosed During Treatment for JAK2 V617F-Positive Primary Myelofibrosis.
Ryu J; Chu D; Park B; Kim M; Cho YU; Hwang SH; Jang S; Seo EJ; Lee JH; Park CJ
Lab Med; 2022 Nov; 53(6):e140-e144. PubMed ID: 35243502
[TBL] [Abstract][Full Text] [Related]
16. Lipocalin-2 is associated with modulation of disease phenotype in a patient with concurrent JAK2-V617F and BCR-ABL mutation.
Nadarajan VS; Ang CH; Bee PC
Eur J Haematol; 2012 Feb; 88(2):175-8. PubMed ID: 21950422
[TBL] [Abstract][Full Text] [Related]
17. The Polymorphisms in LNK Gene Correlated to the Clinical Type of Myeloproliferative Neoplasms.
Chen Y; Fang F; Hu Y; Liu Q; Bu D; Tan M; Wu L; Zhu P
PLoS One; 2016; 11(4):e0154183. PubMed ID: 27111338
[TBL] [Abstract][Full Text] [Related]
18. Chronic myeloid leukemia with e14a3 BCR-ABL transcript: analysis of characteristics and prognostic significance.
Gui X; Zhang Y; Pan J; Qiu H; Cen J; Xue Y; Chen S; Shen H; Yao L; Zhang J; Wu Y; Chen Y
Leuk Lymphoma; 2015; 56(12):3343-7. PubMed ID: 25962435
[TBL] [Abstract][Full Text] [Related]
19. [BCR-ABL1-positive chronic myeloid leukemia emerging in a patient with secondary myelofibrosis harboring the JAK2-V617F mutation].
Amemiya A; Ito Y; Ishibashi Y; Saito Y; Katagiri S; Suguro T; Asano M; Yoshizawa S; Akahane D; Tanaka Y; Fujimoto H; Okabe S; Gotoh M; Tauchi T; Ohyashiki K
Rinsho Ketsueki; 2017; 58(4):298-302. PubMed ID: 28484156
[TBL] [Abstract][Full Text] [Related]
20. Concurrent JAK2-Positive Myeloproliferative Disorder and Chronic Myelogenous Leukemia: A Novel Entity? A Case Report With Review of the Literature.
Bader G; Dreiling B
J Investig Med High Impact Case Rep; 2019; 7():2324709619832322. PubMed ID: 30803277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]